BioNTech raised to buy at Jefferies on new cancer drug
BioNTech (NASDAQ:BNTX) shares traded higher on Tuesday after Jefferies upgraded the German COVID-19 vaccine maker to Buy from ...
Decoding BioNTech's Options Activity: What's the Big Picture?
Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...
Zacks.com on MSN8d
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.
Market Whales and Their Recent Bets on BNTX Options
With a volume of 492,652, the price of BNTX is up 6.46% at $111.78. RSI indicators hint that the underlying stock may be ...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
stocknews7d
3 Healthcare Stocks With High Analyst Price Targets
Recent innovations, successful trials, and increased research and development spending in the healthcare sector further boost ...
Summit boosts Instil, BioNTech as lead drug beats Merck’s Keytruda
Summit Therapeutics (SMMT) boost Instil Bio (TIL) and BioNTech (BNTX) as its PD-1/VEGF bispecific antibody outperforms ...
Buy Rating Affirmed for BioNTech SE Following Promising Clinical Trial Results in Oncology
H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on September 9. Robert Burns has ...